ESID
  • Users Online: 115
  • Print this page
  • Email this page
 
REVIEW ARTICLE
Ahead of Print

Neuromuscular weakness syndromes from immune checkpoint inhibitors: A case series and literature review


1 Department of Neuro-Oncology, Hartford Health Care Medical Group, Hartford Hospital, Hartford, CT, USA
2 Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States
3 Department of Neuro-Oncology Branch, National Cancer Institute, Bethesda, MD, USA

Correspondence Address:
Ahmad Daher,
Department of Neuro.Oncology, Hartford HealthCare Medical Group, Hartford Hospital, 85 Seymour Street, Suite 227, Hartford, CT 06106
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JIPO.JIPO_3_19

Immune checkpoint inhibitors (CPIs) (anti-cytotoxic T-lymphocyte antigen-4, anti-programmed death 1, and anti-programmed death-ligand 1) have transformed the landscape of cancer therapy. However, their increasing use has unleashed immune-related adverse events in various organs, among which neurologic ones, while rare, are increasingly being recognized and remain incompletely characterized. Herein, we report five patients with nonmelanoma cancers who developed weakness after receiving CPIs. The etiology was attributed to radiculoneuritis (one patient), myositis (one patient), Miller Fisher/myasthenia gravis (MG) (one patient), neuropathy/myositis/MG (one patient), and myositis/MG (one patient). Weakness developed after a median of two doses (range: 1–3) and 4 weeks (range: 3–10) from initiation of therapy. Two patients had severe manifestations without improvement while the other three experienced partial improvement despite discontinuation of the CPI (s) and initiation of immunosuppressive therapy. A review of literature identified 62 similar cases. This report highlights the challenges in the diagnosis and management of neurologic adverse events related to the use of CPIs. It also addresses the crucial need for early recognition, proper workup, and better biomarkers to help improve the outcomes of these adverse events.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Daher A
    -  Matsuoka CK
    -  Loghin ME
    -  Penas-Prado M
    -  Tummala S
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed208    
    PDF Downloaded18    

Recommend this journal